Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugemalimab plus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma
NCT04187352Phase 3Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Dec 2019
- Primary completion
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of sugemalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by CStone Pharmaceuticals. Started Dec 2019; status: completed.
02
Drugs
sugemalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04187352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04187352.